TG Therapeutics Inc
NASDAQ:TGTX

Watchlist Manager
TG Therapeutics Inc Logo
TG Therapeutics Inc
NASDAQ:TGTX
Watchlist
Price: 31.92 USD -0.87%
Market Cap: 5B USD
Have any thoughts about
TG Therapeutics Inc?
Write Note

TG Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TG Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
TG Therapeutics Inc
NASDAQ:TGTX
Revenue
$264.8m
CAGR 3-Years
295%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

TG Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
TG Therapeutics Inc

Not Available

Breakdown by Segments
TG Therapeutics Inc

Total Revenue: 233.7m USD
100%
License: 141.7m USD
60.6%
License Revenue: 140.2m USD
60%
Product: 92m USD
39.4%
Other Revenue: 1.5m USD
0.6%
Show More
Show Less

TG Therapeutics Inc
Glance View

Market Cap
4.9B USD
Industry
Biotechnology

TG Therapeutics Inc. stands at the intersection of innovation and ambition in the biopharmaceutical industry, with its eyes set firmly on revolutionizing the treatment of B-cell diseases. Founded by Michael S. Weiss, a proven leader in the biopharma sector, this company has carved a niche by focusing on the development and commercialization of novel therapies for cancer and autoimmune diseases. Central to its strategy is harnessing the science behind B-cells, which play a crucial role in the immune system and are often implicated in malignancies such as lymphoma and leukemia. TG Therapeutics builds its business model around creating value through its clinical development pipeline, championed by therapies like ublituximab and umbralisib. These treatments, which target different pathways within B-cells, illustrate the company’s commitment to advancing precision medicine. Revenue generation for TG Therapeutics hinges on successfully bringing its innovative therapies to market. The company follows a path similar to many in the biotech sphere: investing significantly in research and development to shepherd promising drug candidates through clinical trials. Once a therapy gains regulatory approval, TG Therapeutics moves into the commercialization phase, seeking to monetize its investments through sales. The company's ability to navigate regulatory pathways, establish strategic partnerships, and optimize its commercial efforts is crucial to converting its scientific prowess into financial returns. As a public company, it also utilizes equity financing to fund its expansive R&D endeavors, ensuring that it remains at the forefront of tackling some of the most challenging and prevalent diseases today.

TGTX Intrinsic Value
27.99 USD
Overvaluation 12%
Intrinsic Value
Price

See Also

What is TG Therapeutics Inc's Revenue?
Revenue
264.8m USD

Based on the financial report for Sep 30, 2024, TG Therapeutics Inc's Revenue amounts to 264.8m USD.

What is TG Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
295%

Over the last year, the Revenue growth was 40%. The average annual Revenue growth rates for TG Therapeutics Inc have been 295% over the past three years .

Back to Top